Eslam M, Valenti L, Romeo S (2018) Genetics and epigenetics of NAFLD and NASH: clinical impact. J Hepatol 68:268–279

Article  CAS  PubMed  Google Scholar 

Neuschwander-Tetri BA (2020) Therapeutic landscape for NAFLD in 2020. Gastroenterology 158:1984-1998.e1983

Article  CAS  PubMed  Google Scholar 

Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679–689

Article  CAS  PubMed  Google Scholar 

Porro S et al (2020) Dysmetabolic adipose tissue in obesity: morphological and functional characteristics of adipose stem cells and mature adipocytes in healthy and unhealthy obese subjects. J Endocrinol Invest 44:921–941

Article  PubMed  Google Scholar 

Hosokawa Y et al (2023) Adipose tissue insulin resistance exacerbates liver inflammation and fibrosis in a diet-induced NASH model. Hepatol Commun. https://doi.org/10.1097/HC9.0000000000000161

Article  PubMed  PubMed Central  Google Scholar 

Younossi ZM et al (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77:1335–1347

Article  PubMed  Google Scholar 

Diehl AM, Day C (2017) Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med 377:2063–2072

Article  CAS  PubMed  Google Scholar 

Sheka AC et al (2020) Nonalcoholic steatohepatitis: a review. JAMA 323:1175–1183

Article  CAS  PubMed  Google Scholar 

Younossi Z et al (2018) Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15:11–20

Article  PubMed  Google Scholar 

Cotter TG, Rinella M (2020) Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology 158:1851–1864

Article  CAS  PubMed  Google Scholar 

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ (2018) Mechanisms of NAFLD development and therapeutic strategies. Nat Med 24:908–922

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diehl AM, Farpour-Lambert NJ, Zhao L, Tilg H (2019) Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease. Nat Metab 1:1027–1029

Article  PubMed  Google Scholar 

Johnston MP, Patel J, Byrne CD (2020) Multi-drug approaches to NASH: what’s in the development pipeline? Expert Opin Investig Drugs 29:143–150

Article  CAS  PubMed  Google Scholar 

Rinella ME (2015) Nonalcoholic fatty liver disease: a systematic review. JAMA 313:2263–2273

Article  CAS  PubMed  Google Scholar 

Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62:S47-64

Article  PubMed  Google Scholar 

Dewidar B, Kahl S, Pafili K, Roden M (2020) Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 111:154299

Article  CAS  PubMed Central  Google Scholar 

Reimer KC, Wree A, Roderburg C, Tacke F (2020) New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 14:8–23

Article  PubMed  Google Scholar 

Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E (2019) The role of the microbiome in NAFLD and NASH. EMBO Mol Med. https://doi.org/10.15252/emmm.201809302

Article  PubMed  Google Scholar 

Lang S, Schnabl B (2020) Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. Cell Host Microbe 28:233–244

Article  CAS  PubMed  PubMed Central  Google Scholar 

Federico A, Dallio M, Godos J, Loguercio C, Salomone F (2016) Targeting gut-liver axis for the treatment of nonalcoholic steatohepatitis: translational and clinical evidence. Transl Res 167:116–124

Article  CAS  PubMed  Google Scholar 

Singh S, Osna NA, Kharbanda KK (2017) Treatment options for alcoholic and non-alcoholic fatty liver disease: a review. World J Gastroenterol 23:6549–6570

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sumida Y et al (2020) Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Expert Opin Pharmacother 21:953–967

Article  CAS  PubMed  Google Scholar 

Chen G, Kang W, Li W, Chen S, Gao Y (2022) Oral delivery of protein and peptide drugs: from non-specific formulation approaches to intestinal cell targeting strategies. Theranostics 12:1419–1439

Article  PubMed  PubMed Central  Google Scholar 

Harrison SA et al (2021) Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med 27:1262–1271

Article  CAS  PubMed  Google Scholar 

Hartman ML et al (2020) Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43:1352–1355

Article  CAS  PubMed  PubMed Central  Google Scholar 

Albhaisi SAM, Sanyal AJ (2021) New drugs for NASH. Liver Int 41(Suppl 1):112–118

Article  PubMed  Google Scholar 

Younossi ZM et al (2019) Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394:2184–2196

Article  CAS  PubMed  Google Scholar 

Eslam M, Alvani R, Shiha G (2019) Obeticholic acid: towards first approval for NASH. Lancet 394:2131–2133

Article  PubMed  Google Scholar 

Ratziu V, Friedman SL (2020) Why do so many NASH trials fail? Gastroenterology 165:5–10

Article  PubMed  Google Scholar 

Qian T et al (2022) Molecular Signature Predictive of Long-Term Liver Fibrosis Progression to Inform Antifibrotic Drug Development. Gastroenterology 162:1210–1225

Article  CAS  PubMed  Google Scholar 

Tsochatzis EA (2022) Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design. Lancet Gastroenterol Hepatol 7:586–587

Article  PubMed  Google Scholar 

Safari Z, Gérard P (2019) The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Mol Life Sci 76:1541–1558

Article  CAS  PubMed  Google Scholar 

Brunt EM et al (2015) Nonalcoholic fatty liver disease. Nat Rev Dis Primers 1:15080

Article  PubMed  Google Scholar 

Neuschwander-Tetri BA (2017) Non-alcoholic fatty liver disease. BMC Med 15:45

Article  PubMed  PubMed Central  Google Scholar 

Fuchs A et al (2021) Associations among adipose tissue immunology, inflammation, exosomes and insulin sensitivity in people with obesity and nonalcoholic fatty liver disease. Gastroenterology 161:968-981.e912

Article  CAS  PubMed  Google Scholar 

Aron-Wisnewsky J et al (2020) Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 17:279–297

Article  PubMed  Google Scholar 

Zhang X et al (2021) Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut 70:761–774

Article  CAS  PubMed  Google Scholar 

Kazankov K et al (2019) The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol 16:145–159

Article  CAS  PubMed  Google Scholar 

Xu X et al (2022) Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). Signal Transduct Target Ther 7:287

Article  PubMed  PubMed Central  Google Scholar 

Piccinin E, Villani G, Moschetta A (2019) Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators. Nat Rev Gastroenterol Hepatol 16:160–174